ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment

References

• Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. 2017;66(8):1463–1473. doi:10.1136/gutjnl-2016-311421
   PubMed Web of Science ®Google Scholar
• Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology. 2015;4(3):e976052. doi:10.4161/2162402X.2014.976052
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014
   PubMed Web of Science ®Google Scholar
• Cheng H, Janakiram M, Borczuk A, et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res. 2017;23(3):825–832. doi:10.1158/1078-0432.CCR-15-3071
   PubMed Web of Science ®Google Scholar
• Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115–123. doi:10.1016/j.humpath.2018.08.020
   PubMed Web of Science ®Google Scholar
• Rau TT, Atreya R, Aust D, et al. Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. J Pathol Clin Res. 2016;2(2):113–124. doi:10.1002/cjp2.41
   PubMedGoogle Scholar
• Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature. 2001;409(6816):105–109. doi:10.1038/35051113
   PubMed Web of Science ®Google Scholar
• Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409(6816):97–101. doi:10.1038/35051100
   PubMed Web of Science ®Google Scholar
• Solinas C, Gu-Trantien C, Willard-Gallo K. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open. 2020;5(1):Jan. doi:10.1136/esmoopen-2019-000544
   Google Scholar
• Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 1999;402(6763):827–832. doi:10.1038/45582
   PubMed Web of Science ®Google Scholar
• Metzger TC, Long H, Potluri S, et al. ICOS Promotes the Function of CD4+ effector T Cells during Anti-OX40–mediated tumor rejection. Cancer Res. 2016;76(13):3684–3689. doi:10.1158/0008-5472.CAN-15-3412
   Google Scholar
• Zhang Y, Luo Y, Qin SL, et al. The clinical impact of ICOS signal in colorectal cancer patients. Oncoimmunology. 2016;5(5):e1141857. doi:10.1080/2162402X.2016.1141857
   PubMed Web of Science ®Google Scholar
• Urakawa S, Yamasaki M, Makino T, et al. The impact of ICOS(+) regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy. Cancer Immunol Immunother. 2021;70(2):443–452. doi:10.1007/s00262-020-02696-4
   Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112. doi:10.1038/nature08460
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X, Jin Z, et al. Clinical impact of X-ray repair cross-complementary 1 (XRCC1) and the immune environment in colorectal adenoma-carcinoma pathway progression. J Inflamm Res. 2021;14:5403–5417. doi:10.2147/JIR.S331010
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Yoshimura K, Inoue Y, et al. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer. Oncoimmunology. 2021;10(1):1962656. doi:10.1080/2162402X.2021.1962656
   PubMed Web of Science ®Google Scholar
• Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep. 2015;3(4):269–276. doi:10.1093/gastro/gov046
   Google Scholar
• Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12(6):621–628. doi:10.1586/erm.12.46
   PubMed Web of Science ®Google Scholar
• Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med. 2016;14:21. doi:10.1186/s12967-016-0772-5
   PubMed Web of Science ®Google Scholar
• Roy HK, Turzhitsky V, Wali R, et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut. 2017;66(2):285–292. doi:10.1136/gutjnl-2015-309996
   Google Scholar
• Hwang HS, Kim D, Choi J. Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors. J Immunother Cancer. 2021;9(10):Oct. doi:10.1136/jitc-2021-002797
   Google Scholar
• Lohning M, Hutloff A, Kallinich T, et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med. 2003;197(2):181–193. doi:10.1084/jem.20020632
   Google Scholar
• Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity. 2008;28(6):870–880. doi:10.1016/j.immuni.2008.03.018
   PubMed Web of Science ®Google Scholar
• Craig SG, Humphries MP, Alderdice M, et al. Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. Br J Cancer. 2020;123(8):1280–1288. doi:10.1038/s41416-020-0985-5
   PubMed Web of Science ®Google Scholar
• Viveiros N, Flores BC, Lobo J, et al. Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies. Clin Transl Immunology. 2022;11(9):e1402. doi:10.1002/cti2.1402
   Google Scholar
• Nagase H, Takeoka T, Urakawa S, et al. ICOS(+) Foxp3(+) TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140(3):686–695. doi:10.1002/ijc.30475
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res. 2012;72(23):6130–6141. doi:10.1158/0008-5472.CAN-12-2409
   PubMed Web of Science ®Google Scholar
• Han Y, Dong Y, Yang Q, et al. Acute myeloid leukemia cells express ICOS ligand to promote the expansion of regulatory T cells. Front Immunol. 2018;9:2227. doi:10.3389/fimmu.2018.02227
   Google Scholar
• Liu X, Yu H, Yan C, et al. Plasmacytoid dendritic cells and ICOS(+) Regulatory T cells predict poor prognosis in gastric cancer: a pilot study. J Cancer. 2019;10(26):6711–6715. doi:10.7150/jca.34826
   Google Scholar
• Yan K, Bai B, Ren Y, et al. The comparable microenvironment shared by colorectal adenoma and carcinoma: an evidence of stromal proteomics. Front Oncol. 2022;12:848782. doi:10.3389/fonc.2022.848782
   Google Scholar
• Zhu XW, Zhu HZ, Zhu YQ, Feng MH, Qi J, Chen ZF. Foxp3 expression in CD4(+)CD25(+)Foxp3(+) regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity. J Huazhong Univ Sci Technolog Med Sci. 2016;36(5):677–682. doi:10.1007/s11596-016-1644-1
   Google Scholar
• Kornete M, Sgouroudis E, Piccirillo CA. ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice. J Immunol. 2012;188(3):1064–1074. doi:10.4049/jimmunol.1101303
   PubMed Web of Science ®Google Scholar
• Chen Y, Shen S, Gorentla BK, Gao J, Zhong XP. Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol. 2012;188(4):1698–1707. doi:10.4049/jimmunol.1102448
   PubMed Web of Science ®Google Scholar
• Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574(7780):696–701. doi:10.1038/s41586-019-1671-8
   PubMed Web of Science ®Google Scholar